Top Markets
Coin of the day
Annovis Bio, Inc. Annovis Bio, Inc.

Annovis Bio, Inc.

ANVS
Rank in Stocks #23205
Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on... Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for Alzheimer's and Parkinson's diseases. This compound is also currently being evaluated in clinical studies for Alzheimer's disease in individuals with Down Syndrome, as well as for various other chronic neurodegenerative conditions. Beyond Buntanetap, Annovis Bio is developing ANVS405 to offer protection against traumatic brain injury and stroke. Additionally, ANVS301 is progressing through Phase I clinical trials, aiming to enhance cognitive capabilities in the later stages of Alzheimer's disease and broader dementia. The company was founded in 2008 and operates out of Berwyn, Pennsylvania.
Share Price
$1.81
Last synced: 2026-08-21
Market Cap
$77.00M
Change (1 day)
1.30%
Change (1 year)
-23.63%
Country
US
Trade Annovis Bio, Inc. (ANVS)

Category

Stock price history for Annovis Bio, Inc. (ANVS)
Highest end of day price: $1.82 on 2026-08-01

Lowest end of day price: $7.71 on 2020-01-01
Stock price history of Annovis Bio, Inc. from 2020 to 2026
Annual Stock Price Performance
Year Performance
2026 (TTM) -38.81%
2025 -26.28%
2024 -55.51%
2023 0.70%
2022 -41.39%
2021 233.32%
2020 0.00%
Stock price for similar companies or competitors
Company Stock price Change 1y% Country
$547.71 38.62%
US
$1.04K 58.06%
NL
$145.75 437.43%
US
$118.70 -15.60%
AU
$770.19 8.98%
CH